GLOBAL BLOOD THERAPEUTICS IN's ticker is GBT and the CUSIP is 37890U108. A total of 208 filers reported holding GLOBAL BLOOD THERAPEUTICS IN in Q4 2021. The put-call ratio across all filers is 0.56 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $5,361,000 | +112.1% | 78,720 | -0.5% | 0.01% | +125.0% |
| Q2 2022 | $2,528,000 | -4.4% | 79,124 | +3.7% | 0.00% | +33.3% |
| Q1 2022 | $2,644,000 | +11.2% | 76,330 | -6.0% | 0.00% | 0.0% |
| Q4 2021 | $2,377,000 | +19.1% | 81,218 | +3.7% | 0.00% | 0.0% |
| Q3 2021 | $1,995,000 | -35.1% | 78,293 | -10.8% | 0.00% | -25.0% |
| Q2 2021 | $3,074,000 | -32.4% | 87,765 | -21.3% | 0.00% | -33.3% |
| Q1 2021 | $4,545,000 | -6.4% | 111,540 | -0.5% | 0.01% | -14.3% |
| Q4 2020 | $4,855,000 | -18.8% | 112,102 | +3.4% | 0.01% | -30.0% |
| Q3 2020 | $5,979,000 | -6.0% | 108,439 | +7.6% | 0.01% | -9.1% |
| Q2 2020 | $6,361,000 | +41.4% | 100,763 | +14.4% | 0.01% | +10.0% |
| Q1 2020 | $4,498,000 | -36.0% | 88,046 | -0.5% | 0.01% | -16.7% |
| Q4 2019 | $7,033,000 | +60.6% | 88,482 | -2.0% | 0.01% | +33.3% |
| Q3 2019 | $4,380,000 | -0.7% | 90,269 | +7.7% | 0.01% | 0.0% |
| Q2 2019 | $4,409,000 | +1.6% | 83,823 | +2.3% | 0.01% | 0.0% |
| Q1 2019 | $4,339,000 | +35.0% | 81,973 | +4.7% | 0.01% | +28.6% |
| Q4 2018 | $3,213,000 | +10.6% | 78,261 | +2.4% | 0.01% | +16.7% |
| Q3 2018 | $2,905,000 | -15.9% | 76,442 | -0.0% | 0.01% | -14.3% |
| Q2 2018 | $3,456,000 | +20.6% | 76,470 | +28.9% | 0.01% | +16.7% |
| Q1 2018 | $2,865,000 | +25.1% | 59,314 | +1.9% | 0.01% | +20.0% |
| Q4 2017 | $2,290,000 | +24.9% | 58,199 | -1.5% | 0.01% | +25.0% |
| Q3 2017 | $1,834,000 | +2.6% | 59,058 | -9.7% | 0.00% | 0.0% |
| Q2 2017 | $1,788,000 | +22.9% | 65,390 | +65.6% | 0.00% | +33.3% |
| Q1 2017 | $1,455,000 | +195.1% | 39,490 | +15.8% | 0.00% | +200.0% |
| Q4 2016 | $493,000 | -38.9% | 34,090 | -2.6% | 0.00% | -50.0% |
| Q3 2016 | $807,000 | +65.0% | 34,990 | +18.7% | 0.00% | +100.0% |
| Q2 2016 | $489,000 | +108.1% | 29,490 | +99.1% | 0.00% | 0.0% |
| Q1 2016 | $235,000 | -43.0% | 14,815 | +16.2% | 0.00% | 0.0% |
| Q4 2015 | $412,000 | -22.4% | 12,745 | +1.2% | 0.00% | 0.0% |
| Q3 2015 | $531,000 | – | 12,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alerce Investment Management, L.P. | 356,270 | $24,262,000 | 23.36% |
| Twin Securities, Inc. | 376,669 | $25,651,000 | 11.94% |
| Paradigm Biocapital Advisors LP | 1,175,879 | $80,077,000 | 10.68% |
| Chicago Capital Management, LLC | 246,246 | $16,769,000 | 9.12% |
| HARVEST MANAGEMENT LLC | 141,500 | $9,636,000 | 7.78% |
| Fernwood Investment Management, LLC | 174,724 | $11,899,000 | 5.02% |
| ArchPoint Investors | 168,725 | $11,490,000 | 4.69% |
| HAVENS ADVISORS LLC | 46,000 | $3,133,000 | 4.69% |
| Perceptive Advisors | 2,322,247 | $158,145,000 | 4.59% |
| Crabel Capital Management, LLC | 112,680 | $7,674,000 | 4.48% |